Jump to main content
Jump to site search


Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment

Author affiliations

Abstract

Here we report a novel mechanism for triggering drug release in the polydopamine (PDA)-coated magnetic CuCo2S4 core–shell nanostructure by glutathione (GSH) triggered degradation of PDA for release. In the design, we used PDA coated CuCo2S4 as the nanocarrier with polyethylene glycol and folic acid targeting molecules to ensure the safe delivery of doxorubicin (DOX) to cancer cells. In addition, the controlled release could be enforced by taking advantage of the pH sensitivity of PDA to tumor acidic environments. The targeting and treatment of HeLa cancer cells were very effective and the killing was more efficient at higher levels of GSH. Furthermore, the designed system not only could be used for drug delivery but also could combine photothermal therapy with chemotherapy in a synergetic way. Plus, the system could be used for magnetic resonance imaging (MRI), which is beneficial for imaging-guided treatment.

Graphical abstract: Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment

Back to tab navigation

Supplementary files

Publication details

The article was received on 08 Jul 2019, accepted on 12 Aug 2019 and first published on 14 Aug 2019


Article type: Paper
DOI: 10.1039/C9TB01400D
J. Mater. Chem. B, 2019, Advance Article

  •   Request permissions

    Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment

    Y. Hao, A. Zheng, T. Guo, Y. Shu, J. Wang, O. Johnson and W. Chen, J. Mater. Chem. B, 2019, Advance Article , DOI: 10.1039/C9TB01400D

Search articles by author

Spotlight

Advertisements